Infliximab and rate of mechanical ventilation in COVID-19 patients:

The rate of mechanical ventilation was not statistically significant between the two groups according to this meta-analysis.
Monoclonal antibodies could slightly decrease the rate of mechanical ventilation in hospitalized patients with COVID-19 (relative risk 0.74; 95% confidence interval [CI], 0.60-0.9; I2 = 20%) [24].
Infliximab may potentially induce pulmonary complications like non-infectious interstitial lung disease and thereby should be cautiously prescribed in patients with SARS-CoV-2 [26].